Please assess the completion status of the following clinical trial:

Trial Title: Shoulder Corticosteroid Injection in Diabetic Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Consent to participate in the study.~* Severe overall pain and night pain: Numerical Rating Scale (NRS) for pain\[8\] above or equal to 60/100; the scale was modified from 0-10 to 0-100 (0 = no pain 100 = unbearable pain).~* No significant improvement after at least 2 courses of physiotherapy (including direct assistance from a physical therapist with specific exercises, manual therapy, and physical agents in order to reduce inflammation and pain).~* Clinical signs of subacromial tendinobursitis, with or without signs of rotator cuff tear, defined as positive Neer, Yocum and Hawkins tests\[9-15\]. Pain experienced during the execution of these tests needed to reproduce the type of pain that patients complained the most.~* No indication for surgery due to the age, concomitant comorbidities or patient's refusal to undergo surgery.~* Well-controlled type-2 diabetes, defined as:~  * Fasting and pre-prandial blood glucose levels in the range of 90- 150mg/dL.~ * Hb1Ac \<64mmol/mol (corresponding to 8%) measured within 6 months.~* A device for self-measurement of blood sugar levels at home~* Patients need to have a recent (within 6 months) x-ray and an MRI or ultrasound of the affected shoulder~Exclusion Criteria:~* Corticosteroid treatment in the past 3 months.~* Complaints of shoulder stiffness more than shoulder pain.~* Symptomatic glenohumeral arthritis defined as shoulder stiffness plus moderate radiographic signs of arthritis (grade \>2 according to Hamada classification and grade \>1 according to Samilson-Prieto classification for eccentric and concentric arthritis respectively).~* Shoulder trauma within 3 months of inclusion evaluation for in this study.~* High blood pressure values (systolic blood pressure \>140mmHg, diastolic blood pressure \>80mmHg).~* Glaucoma.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).